Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ravic

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Postgraduate Medical Journal|November 1, 1993
A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicamM Ravic, I Salas-Herrera, A Johnston, et al.
Postgraduate Medical Journal|January 1, 1990
Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidationS J Warrington, Y Lewis, A Dawnay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG)C J Punt, P Fumoleau, B van de Walle, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)C Terret, S Zanetta, H Roché, et al.
Anti-Cancer Drugs|July 11, 2003
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human bloodH J G D van den Bongard, D Pluim, R C A M van Waardenburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validationCh Van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Postgraduate Medical Journal|November 1, 1993
A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicamM Ravic, I Salas-Herrera, A Johnston, et al.
Postgraduate Medical Journal|January 1, 1990
Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidationS J Warrington, Y Lewis, A Dawnay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG)C J Punt, P Fumoleau, B van de Walle, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)C Terret, S Zanetta, H Roché, et al.
Anti-Cancer Drugs|July 11, 2003
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human bloodH J G D van den Bongard, D Pluim, R C A M van Waardenburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validationCh Van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 2